• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

    22.95 -0.28 (-1.18%)
    Streaming Delayed Price Updated: 11:39 AM EDT, Mar 17, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 102,133
    Open 23.46
    Bid (Size) 22.87 (100)
    Ask (Size) 23.04 (300)
    Prev. Close 23.23
    Today's Range 22.57 - 23.95
    52wk Range 6.110 - 44.60
    Shares Outstanding 41,793,412
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Zenas BioPharma
    Via GlobeNewswire

    Performance

    YTD
    -33.5%
    -33.5%
    1 Month
    -14.3%
    -14.3%
    3 Month
    -29.6%
    -29.6%
    6 Month
    +4.6%
    +4.6%
    1 Year
    +172.3%
    +172.3%

    More News

    Read More
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
    From Zenas BioPharma
    Via GlobeNewswire
    Why Is ZBIO Stock Falling Pre-Market Today? ↗
    Via Stocktwits
    News headline image
    Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zenas BioPharma, Inc. – ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    How Royalty Pharma Prints Cash Without Biotech's Biggest Risks ↗
    Via MarketBeat
    News headline image
    1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data ↗
    Via MarketBeat
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
    From Zenas BioPharma
    Via GlobeNewswire
    News headline image
    Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948 ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug ↗
    Via Benzinga
    News headline image
    Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
    From Zenas BioPharma
    Via GlobeNewswire

    Frequently Asked Questions

    Is Zenas BioPharma, Inc. - Common Stock publicly traded?
    Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
    What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
    Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
    The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
    What is the current price of Zenas BioPharma, Inc. - Common Stock?
    The current price of Zenas BioPharma, Inc. - Common Stock is 22.95
    When was Zenas BioPharma, Inc. - Common Stock last traded?
    The last trade of Zenas BioPharma, Inc. - Common Stock was at 03/17/26 11:39 AM ET
    What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?
    The market capitalization of Zenas BioPharma, Inc. - Common Stock is 959.37M
    How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?
    Zenas BioPharma, Inc. - Common Stock has 959M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.